Methadone for cancer pain.

Area of Science:

• Palliative Care and Pain Management
• Oncology
• Pharmacology

Background:

• Methadone is an opioid analgesic utilized for managing cancer pain, with potential applications in neuropathic pain.
• This review is an update of a previous Cochrane review, aiming to provide evidence-based palliative care insights.
• The study addresses the need for a formal appraisal of methadone compared to other analgesics in cancer pain management.

Purpose of the Study:

• To evaluate the effectiveness and safety of methadone for analgesia in patients experiencing cancer pain.
• To compare methadone's efficacy and tolerability against other analgesics, including morphine.

Main Methods:

• A systematic search of multiple databases (MEDLINE, EMBASE, CancerLit, CINAHL, Cochrane) was conducted up to September 2006.
• Included studies were randomized controlled trials (RCTs) comparing methadone with active or placebo comparators.
• Outcomes assessed included pain intensity reduction, adverse effects, patient attrition, satisfaction, and quality of life.

Main Results:

• Nine RCTs involving 459 patients were included, comparing methadone with active opioid comparators like morphine.
• Methadone demonstrated broadly similar analgesic efficacy and tolerability compared to morphine.
• Complete adverse event data were available for all studies, though complete pain data sets were limited.

Conclusions:

• Methadone exhibits comparable analgesic efficacy to morphine in cancer pain management.
• No superiority of methadone was found for neuropathic pain in the included studies.
• Prolonged use of methadone may lead to accumulation and delayed adverse effects, necessitating experienced clinical management and careful monitoring.